Sickle Cell Disease (SCD) Treatment Market Size, Share Analysis and Growth Forecast 2030 - Reports and Data

The global sickle cell disease treatment market size was USD 1.70 Billion in 2021 and is expected to register a revenue CAGR of 18.1% over the forecast period, according to the latest report by Reports and Data. Increase in consumer awareness about sickle cell disease and new product launches are key factors driving market revenue growth.

Increasing demand for sickle cell disease treatment is mainly attributed to rising cases of sickle cell disease in countries such as the U.S., Africa, and others. This inherited disease causes red blood cells to take the shape of a sickle and span of Red Blood Cells (RBCs) reduces, which ultimately results in shortage of RBCs in body. According to international organizations, such as American Society of Hematology, around 70,000 to 100,000 people in the U.S. suffer from sickle cell disease. In addition, as per World Health Organization (WHO), 5% of total population suffers from a defective gene for blood-related disorders such as sickle cell disease and thalassemia.

Access Free sample PDF Copy of the Report (To Understand the Complete Structure of this Report [Summary + TOC]) @

Rapid advancements and significant investments in product research are among other major factors driving market revenue growth. For instance, on 1 December 2021, researchers at University of California San Francisco (UCSF) Benioff Oakland received USD 17 million to conduct innovative trials for treatment of sickle cell disease. This trial will be the first to use Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein (CRISPR-Cas9) technology in humans since other traditional therapies, such as bone marrow transplant, can only be performed in children aged 16 years or lesser. Similarly, market companies are focusing on drug development and getting approval from leading authorities. For instance, on 17 December 2021, Food and Drug Administration (FDA) granted approval for Oxbryta (voxelotor) tablets to treat sickle cell disease in pediatric patients aged 4 up to 11 years.

Some Key Highlights From the Report

    • On 30 October 2022, Novartis AG, which is a pharmaceutical company based in Switzerland announced to launch Adakveo (crizanlizumab) after it had received approval from European Commission (EC) for prevention of recurrent Vaso-Occlusive Crises (VOCs) in patients with sickle cell disease aged 16 years and older. Adakveo binds to P-selectin, a cell adhesion protein that is essential for multicellular interactions that can result in vaso-occlusion. Adakveo has now received regulatory approval in 36 countries, including those that are members of European Union (EU) and the U.S.
    • The blood transfusion segment accounted for largest revenue share in 2021. Market revenue growth of is primarily driven due to high demand for blood transfusions in sickle cell treatment. The transfusion mainly lowers hemoglobin S red blood cells, therefore, limiting its activity of blocking blood vessels. It also increases number of normal red blood cells, thereby increasing amount of hemoglobin in body.
    • The hospitals segment accounted for largest revenue share in 2021. Increasing consumer awareness regarding benefits of availing hospitals is a key factor driving market revenue growth. Hospitals aid in providing routine blood transfusions and frequent monitoring of patients with thalassemia and sickle cell anemia. In addition, it aids in monitoring iron excess, medicine toxicity, growth, development, and psychological well-being of patients. Increasing occurrence of symptoms, such as VOC in patients suffering from sickle cell disease, is another major factor driving revenue growth of this segment. In 2021, according to National Centre of Biological Information (NCBI), VOC was found to be the major cause of hospitalizations among children with sickle cell disease.
    • The North America accounted for largest revenue share in 2021. Increasing investments in healthcare and launch of new products are key factors driving market revenue growth. The U.S. market accounted for largest revenue share owing to presence of market companies such as Bristol Myers Squibb, bluebird bio Inc., and others. In addition, increasing support from government to promote awareness regarding the disease driving market revenue growth.

The ongoing pandemic is significantly changing the dynamics of the pharma and healthcare sector. Various countries are facing challenges such as shortage of medicines, vaccines, healthcare devices in hospitals. This is expected to open lucrative growth opportunities for market players in the coming years.

For Inquiry Before Buying @

Competitive Landscape:

The global market comprises various market players operating at regional and global levels. These key players are adopting various strategies such as R&D investments, license agreements, partnerships, merger and acquisitions, collaborations, and joint ventures to gain robust footing in the market.

Top Companies Profiled in the Report:

Novartis AG, F. Hoffmann-La Roche Ltd, Bristol Myers Squibb Company, Global Blood Therapeutics Inc., Emmaus Medical, Inc., bluebird bio, Inc., Medunik USA, Sangamo Therapeutics, Intellia Therapeutics, Inc., and Addmedica.

Browse Full Report Description with Research Methodology, Table of Content and Infographics @

Sickle Cell Disease (SCD) Treatment Market Segmentation:

Treatment Type Outlook (Revenue, USD Billion; 2019–2030)

  • Blood Transfusion
  • Bone Marrow Transplant
  • Pharmacotherapy

End-Use Outlook (Revenue, USD Billion; 2019–2030)

  • Hospitals
  • Specialty Clinics
  • Others

Regional Outlook:

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., Italy, France, BENELUX, Rest of Europe)
  • Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
  • Latin America (Brazil, Rest of LATAM)
  • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Ask for Customize Research Report @

This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges, that will determine the market’s future growth.

Explore More Industry Research by Reports and Data:

Thoracic Catheters Market, By Product Type (Analog, Accessories, Catheter, Digital), By Application (Plural Effusion, Pneumothorax, Others) and By Region Forecast to 2028 - Reports Details

Travelers Vaccines Market By Composition (Mono Vaccines and Combination Vaccines), By Type (Attenuated Vaccines, Inactive Vaccines, Subunit Vaccines, Toxoid Vaccines, Conjugate Vaccines, DNA Vaccines, and Recombinant Vector Vaccines), By Disease (Influenza, Diphtheria, Hepatitis, and Others), and By Region Forecast to 2028 - Reports Details

Medical Stethoscopes Market, By Form (Manual and Mechanical Stethoscopes, Digital Stethoscopes), By Application (Hospital, Clinics, and Others), and By Region Forecast to 2028 - Reports Details

BCG Vaccine Market By Type (Immune BCG, Therapy BCG), By Application (Pediatrics, Adults), By End Use (Hospitals, Clinics, Others), and By Region Forecast to 2028 - Reports Details

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W
Head of Business Development
Reports And Data | Web:
Direct Line: +1-212-710-1370
LinkedIn | Twitter | Blogs

Read the innovative blog at

Check out our upcoming research report at

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update:


Back to news